REG - Aptamer Group PLC - Biomarker Discovery Service Launch

AptamerAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250827:nRSa7610Wa&default-theme=true

RNS Number : 7610W  Aptamer Group PLC  27 August 2025

 

27 August 2025

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Biomarker Discovery Service Launch

Accelerated platform delivers validated, drug-development-ready biomarkers

with Optimer® ligands in months, not years

New fee-for-service offering creates additional revenue stream in US$62.4bn
global market

 

Aptamer Group plc (AIM: APTA), the leading developer of next-generation
synthetic binders delivering innovation to the life science industry, is
pleased to announce the launch of its biomarker discovery service, creating a
new fee-for-service revenue stream targeting the US$62.4 billion global
biomarker discovery market.

 

Biomarkers are essential molecular indicators of physiological states,
including disease presence and progression, and play a critical role in
enabling targeted drug development, early diagnosis, treatment monitoring and
safety assessment. The identification of new biomarkers is a key driver of
innovation in healthcare, particularly in areas of high unmet medical need
where the absence of suitable biomarkers has historically limited therapeutic
and diagnostic advancement.

 

Aptamer's biomarker discovery service represents a transformative shift from
traditional, time-intensive methods by harnessing its proprietary Optimer®
technology in combination with advanced proteomic analysis, the large-scale
study of proteins in a biological system. This approach enables rapid,
unbiased identification of disease-specific biomarkers by differentiating
healthy and diseased cell states at the molecular level.

 

Crucially, it not only identifies validated biomarkers but also simultaneously
generates high-affinity binding molecules that are ready for immediate
integration into commercial applications. This dual-output capability
significantly accelerates development timelines for pharmaceutical research,
biotechnology innovation and diagnostic test creation, offering a powerful
solution for companies seeking to advance targeted therapies and enable
earlier, more accurate disease detection.

 

Delivered under Aptamer's established fee-for-service model, the new biomarker
discovery offering provides an immediate monetisation opportunity for the
Company with minimal upfront investment and is expected to be revenue
enhancing in the current financial year.

 

Operating within a large and growing market driven by the rise of precision
medicine, the service is well-positioned to capture significant demand from
pharmaceutical, biotech and diagnostic developers. Early interest has already
been demonstrated following the successful internal application of the
platform to identify the biomarker targeted by Aptamer's fibrotic liver
delivery system - highlighting its potential to deliver faster, actionable
insights and validating its commercial relevance.

 

Launching on a fee-for-service basis, the service enables pharmaceutical and
biotechnology partners to accelerate R&D pipelines without significant
capital expenditure, supporting Aptamer's revenue diversification strategy.
More information about the service can be found here:
https://aptamergroup.com/biomarker-discovery-service
(https://aptamergroup.com/biomarker-discovery-service)

 

Dr Arron Tolley, Chief Executive Officer of Aptamer Group, commented: "This
new service builds on our core strength in applying Optimer® libraries to
bind precisely to disease-relevant targets. Following our successful
identification and validation of the biomarker for our fibrotic liver delivery
system, we have seen strong interest from pharmaceutical and biotechnology
companies seeking novel drug targets to strengthen their intellectual property
positions.

 

Our approach enables the discovery of functional biomarkers in a fraction of
the time required by traditional methods, which often take years of screening.
With two additional biomarker discovery projects already progressing in the
lab, we are excited to support our partners in accelerating the development of
new treatments and diagnostics, while expanding the commercial impact of our
Optimer® platform."

 

- Ends -

 

For further information, please contact:

 

 Aptamer Group plc                                               +44 (0) 1904 217 404 

 Dr Arron Tolley, Chief Executive Officer
 SPARK Advisory Partners Limited - Nominated Adviser             +44 (0) 20 3368 3550 

 Andrew Emmott / Jade Bayat 
 Turner Pope Investments (TPI) Limited - Broker                  +44 (0) 20 3657 0050 

 James Pope / Andrew Thacker 
 Northstar Communications Limited - Investor Relations           +44 (0) 113 730 3896

 Sarah Hollins

 

About Aptamer Group

 

Aptamer Group is a leading developer of next-generation synthetic binders
delivering innovation to the life sciences industry. The Group develops
Optimer® binders, advanced molecules that work like antibodies by attaching
to specific targets in the body. These binders are used in medicine,
diagnostic tests, and research tools, offering benefits like high stability,
reliable performance, and lower costs compared to traditional antibodies.

 

Aptamer operates a fee-for-service business in the US$210 billion market for
antibody alternatives, working with all top 10 global pharmaceutical
companies. It is also building valuable Optimer® assets with partners, aiming
for future licensing revenue.

 

Founded in 2008, the Group listed on the London Stock Exchange AIM market in
December 2021 and is headquartered in York, UK.

 

To register for news alerts by email go to
https://aptamergroup.com/investors/investor-news-email-alerts/
(https://aptamergroup.com/investors/investor-news-email-alerts/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDPKABQCBKDOFB